1. Home
  2. ABUS
  3. ABUS News

Latest Arbutus Biopharma Corporation (ABUS) News on April 24, 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
ABUS

GlobeNewswire

a day ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
ABUS

Zacks

24 days ago

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
ABUS

Zacks

24 days ago

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Novo gains Lexicon obesity drug; CRISPR COO to step down
ABUS

BioPharma Dive

a month ago

Novo gains Lexicon obesity drug; CRISPR COO to step down

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
ABUS

Zacks

a month ago

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
ABUS

GlobeNewswire

a month ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious
ABUS

Barrons.com

a month ago

As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious

ABUS

MT Newswires

2 months ago

Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
ABUS

GlobeNewswire

2 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

MT Newswires

2 months ago

Arbutus Biopharma Names Lindsay Androski CEO, Overhauls Board

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
ABUS

GlobeNewswire

2 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy?
ABUS

Insider Monkey

2 months ago

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy?

Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’
ABUS

Insider Monkey

3 months ago

Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?
ABUS

Zacks

3 months ago

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Arbutus Provides 2025 Corporate and Financial Update
ABUS

GlobeNewswire

3 months ago

Arbutus Provides 2025 Corporate and Financial Update

Here’s Why Arbutus (ABUS) Surged in Q3
ABUS

Insider Monkey

5 months ago

Here’s Why Arbutus (ABUS) Surged in Q3

ABUS

Business Wire

5 months ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
ABUS

GlobeNewswire

5 months ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

ABUS

MT Newswires

5 months ago

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
ABUS

GlobeNewswire

5 months ago

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
ABUS

GlobeNewswire

5 months ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus to Present at Jefferies London Healthcare Conference
ABUS

GlobeNewswire

5 months ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...
ABUS

GuruFocus.com

6 months ago

Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...

ABUS

Thomson Reuters StreetEvents

6 months ago

Q3 2024 Arbutus Biopharma Corp Earnings Call

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
ABUS

Zacks

6 months ago

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

ABUS

Associated Press Finance

6 months ago

Arbutus: Q3 Earnings Snapshot

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ABUS

GlobeNewswire

6 months ago

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
ABUS

GlobeNewswire

6 months ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
ABUS

GlobeNewswire

6 months ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
ABUS

GlobeNewswire

7 months ago

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
ABUS

Zacks

7 months ago

Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
ABUS

Zacks

7 months ago

Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

Arbutus to Participate in Two Upcoming Investor Conferences
ABUS

GlobeNewswire

8 months ago

Arbutus to Participate in Two Upcoming Investor Conferences

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
ABUS

Zacks

8 months ago

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
ABUS

Zacks

9 months ago

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

ABUS

Thomson Reuters StreetEvents

9 months ago

Q2 2024 Arbutus Biopharma Corp Earnings Call

ABUS

MT Newswires

9 months ago

Arbutus Biopharma to Reduce Workforce by 40% to Focus on Hepatitis B Treatment Imdusiran

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
ABUS

Zacks

9 months ago

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

ABUS

Associated Press Finance

9 months ago

Arbutus: Q2 Earnings Snapshot

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
ABUS

GlobeNewswire

9 months ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
ABUS

GlobeNewswire

9 months ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
ABUS

Zacks

10 months ago

Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?

ABUS

MT Newswires

a year ago

Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
ABUS

GlobeNewswire

a year ago

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
ABUS

GlobeNewswire

a year ago

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
ABUS

GlobeNewswire

a year ago

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus to Participate in Jefferies Global Healthcare Conference
ABUS

GlobeNewswire

a year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024
ABUS

GlobeNewswire

a year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

ABUS

MT Newswires

a year ago

Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program

ABUS

MT Newswires

a year ago

Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program

ABUS

Business Wire

a year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus to Participate in Two Upcoming Investor Conferences
ABUS

GlobeNewswire

a year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
ABUS

Insider Monkey

a year ago

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript

Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
ABUS

Simply Wall St.

a year ago

Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ABUS

GuruFocus.com

a year ago

Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

ABUS

GuruFocus.com

a year ago

Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
ABUS

Zacks

a year ago

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

ABUS

Associated Press Finance

a year ago

Arbutus: Q1 Earnings Snapshot

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
ABUS

GlobeNewswire

a year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
ABUS

GlobeNewswire

a year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
ABUS

Zacks

a year ago

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
ABUS

GlobeNewswire

a year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
ABUS

GlobeNewswire

a year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?
ABUS

Simply Wall St.

a year ago

Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?

Arbutus to Participate in Two Upcoming Investor Conferences
ABUS

GlobeNewswire

a year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
ABUS

Simply Wall St.

a year ago

Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts
ABUS

Simply Wall St.

a year ago

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript
ABUS

Insider Monkey

a year ago

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript

ABUS

Thomson Reuters StreetEvents

a year ago

Q4 2023 Arbutus Biopharma Corp Earnings Call

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
ABUS

Zacks

a year ago

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials
ABUS

GuruFocus.com

a year ago

Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
ABUS

GlobeNewswire

a year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
ABUS

GlobeNewswire

a year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable
ABUS

Simply Wall St.

a year ago

The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable

JOHN HANCOCK TAX-ADVANTAGED DIVIDEND INCOME FUND NOTICE TO SHAREHOLDERS - SOURCES OF DISTRIBUTION UNDER SECTION 19(a)
ABUS

PR Newswire

a year ago

JOHN HANCOCK TAX-ADVANTAGED DIVIDEND INCOME FUND NOTICE TO SHAREHOLDERS - SOURCES OF DISTRIBUTION UNDER SECTION 19(a)

3 Growth Stocks Down Between 18.4% and 36.2% So Far This Year That Could Recover
ABUS

Motley Fool

a year ago

3 Growth Stocks Down Between 18.4% and 36.2% So Far This Year That Could Recover

Old Second Bancorp, Inc. (NASDAQ:OSBC) Q4 2023 Earnings Call Transcript
ABUS

Insider Monkey

a year ago

Old Second Bancorp, Inc. (NASDAQ:OSBC) Q4 2023 Earnings Call Transcript

Greenfire Resources Announces Operational Update, Including Strong Initial Refill Well Results and New WTI Hedging Program
ABUS

Newsfile

a year ago

Greenfire Resources Announces Operational Update, Including Strong Initial Refill Well Results and New WTI Hedging Program

Spirit Airlines Dives Near Record Lows After JetBlue Warns On Merger Termination
ABUS

Investor's Business Daily

a year ago

Spirit Airlines Dives Near Record Lows After JetBlue Warns On Merger Termination

Compared to Estimates, Old Second Bancorp (OSBC) Q4 Earnings: A Look at Key Metrics
ABUS

Zacks

a year ago

Compared to Estimates, Old Second Bancorp (OSBC) Q4 Earnings: A Look at Key Metrics

What Is Energy Recovery, Inc.'s (NASDAQ:ERII) Share Price Doing?
ABUS

Simply Wall St.

a year ago

What Is Energy Recovery, Inc.'s (NASDAQ:ERII) Share Price Doing?

Newmark Group's Fourth Quarter and Full Year 2023 Financial Results Announcement to be Issued Prior to Market Open on Thursday, February 22, 2024
ABUS

PR Newswire

a year ago

Newmark Group's Fourth Quarter and Full Year 2023 Financial Results Announcement to be Issued Prior to Market Open on Thursday, February 22, 2024

Precious Metal Prices Trade Sideways After Short-Lived Rally
ABUS

Oilprice.com

a year ago

Precious Metal Prices Trade Sideways After Short-Lived Rally

Title Resources Group Welcomes New Executive
ABUS

PR Newswire

a year ago

Title Resources Group Welcomes New Executive

Why Dada Nexus Plunged and Took JD.com With It
ABUS

Motley Fool

a year ago

Why Dada Nexus Plunged and Took JD.com With It

How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry
ABUS

Zacks

a year ago

How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry

3 No-Brainer Stocks to Buy With $20 Right Now
ABUS

Motley Fool

a year ago

3 No-Brainer Stocks to Buy With $20 Right Now

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
ABUS

GlobeNewswire

a year ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Lindsay Corporation (NYSE:LNN) Q1 2024 Earnings Call Transcript
ABUS

Insider Monkey

a year ago

Lindsay Corporation (NYSE:LNN) Q1 2024 Earnings Call Transcript

Insider Sell: Dynavax Technologies Corp President & COO David Novack Sells 9,000 Shares
ABUS

GuruFocus.com

a year ago

Insider Sell: Dynavax Technologies Corp President & COO David Novack Sells 9,000 Shares

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
ABUS

Business Wire

a year ago

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update

Those who invested in CBIZ (NYSE:CBZ) five years ago are up 203%
ABUS

Simply Wall St.

a year ago

Those who invested in CBIZ (NYSE:CBZ) five years ago are up 203%

JOHN HANCOCK CLOSED-END FUNDS DECLARE MONTHLY DISTRIBUTIONS
ABUS

PR Newswire

a year ago

JOHN HANCOCK CLOSED-END FUNDS DECLARE MONTHLY DISTRIBUTIONS

Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company
ABUS

Simply Wall St.

a year ago

Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company

Zhihu Inc.'s (NYSE:ZH) Intrinsic Value Is Potentially 55% Above Its Share Price
ABUS

Simply Wall St.

a year ago

Zhihu Inc.'s (NYSE:ZH) Intrinsic Value Is Potentially 55% Above Its Share Price

4 Film & Television Production Stocks to Watch on Solid Industry Trends
ABUS

Zacks

a year ago

4 Film & Television Production Stocks to Watch on Solid Industry Trends

Autolus Therapeutics Announces Changes to its Board of Directors
ABUS

GlobeNewswire

a year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Dril-Quip, Inc.'s (NYSE:DRQ) Share Price Matching Investor Opinion
ABUS

Simply Wall St.

a year ago

Dril-Quip, Inc.'s (NYSE:DRQ) Share Price Matching Investor Opinion

BMO Optimistic About Fintech Stocks in 2024; Here Are 3 Top Picks to Keep an Eye On
ABUS

TipRanks

a year ago

BMO Optimistic About Fintech Stocks in 2024; Here Are 3 Top Picks to Keep an Eye On

Sidoti Events, LLC's Virtual December Small-Cap Conference
ABUS

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Share on Social Networks: